EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
Часто задаваемые вопросы
В каком секторе работает Eyepoint Pharmaceuticals Inc (EYPT)?
Eyepoint Pharmaceuticals Inc относится к сектору Здравоохранение.
Какова текущая цена акций Eyepoint Pharmaceuticals Inc (EYPT)?
По последним данным, цена акций Eyepoint Pharmaceuticals Inc составляет 3,62 $, предыдущее закрытие — 3,65 $. За последнюю торговую сессию акции Eyepoint Pharmaceuticals Inc снизились на -0,04 $, что соответствует падению на -0,96%.
Выплачивает ли Eyepoint Pharmaceuticals Inc (EYPT) дивиденды?
Нет, Eyepoint Pharmaceuticals Inc не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Eyepoint Pharmaceuticals Inc (EYPT)?
У компании Eyepoint Pharmaceuticals Inc бета 1.739, что указывает на повышенную волатильность по сравнению с рынком.
